Phage-Microbiota Interactions in the Gut: Implications for Health and Therapeutic Strategies

The diversified ecology of microorganisms, including bacteria, archaea, fungi, protozoa, and viruses known collectively as the gut microbiota, which includes bacteriophages, is crucial to human health because it affects functions like immune system regulation, vitamin production, and pathogen protec...

Full description

Saved in:
Bibliographic Details
Published in:Probiotics and antimicrobial proteins
Main Authors: Naderian, Ramtin, Alibabaei, Farnaz, Paraandavaji, Elham, Dehghan, Parmida, Eslami, Majid
Format: Journal Article
Language:English
Published: United States 01.10.2025
Subjects:
Bacteriophages
Gut microbiota
Microbial diversity
Phage therapy
Immune modulation
ISSN:1867-1306, 1867-1314, 1867-1314
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The diversified ecology of microorganisms, including bacteria, archaea, fungi, protozoa, and viruses known collectively as the gut microbiota, which includes bacteriophages, is crucial to human health because it affects functions like immune system regulation, vitamin production, and pathogen protection. Bacteriophages are viruses that infect bacteria and are increasingly recognized as a viable treatment option for antibiotic-resistant strains, owing to their high host specificity, which enables precise targeting of drug-resistant bacteria while sparing commensal microbiota. The complex relationships between bacteriophages and gut microbiota are examined, with emphasis on their roles in maintaining health and contributing to disease. Gut microbiota homeostasis is influenced by a number of factors, including age, nutrition, and drugs. Bacteriophages, via lytic cycles and lysogenic conversion, influence the gut microbiota composition and microbial community structure. Gaining an understanding of these processes is crucial to appreciating their contribution to the stability and variety of microbes. Recent research highlights the gut phageome's potential for therapeutic interventions by demonstrating its substantial influence on immunological responses and metabolic problems. The study of phage-microbiota interactions has been transformed by cutting-edge technologies, including high-throughput sequencing, CRISPR-Cas systems, and viral metagenomics, which allow for thorough research and the creation of new therapeutics. Even though tailored medicine and pathogen management hold great potential, obstacles such as regulatory difficulties and bacterial resistance call for additional investigation. Phage-based therapeutic strategies are rapidly advancing, ranging from genetically engineered phages and phages with modified capsid proteins designed to enhance efficacy to phage cocktails that target multiple bacterial strains.
AbstractList The diversified ecology of microorganisms, including bacteria, archaea, fungi, protozoa, and viruses known collectively as the gut microbiota, which includes bacteriophages, is crucial to human health because it affects functions like immune system regulation, vitamin production, and pathogen protection. Bacteriophages are viruses that infect bacteria and are increasingly recognized as a viable treatment option for antibiotic-resistant strains, owing to their high host specificity, which enables precise targeting of drug-resistant bacteria while sparing commensal microbiota. The complex relationships between bacteriophages and gut microbiota are examined, with emphasis on their roles in maintaining health and contributing to disease. Gut microbiota homeostasis is influenced by a number of factors, including age, nutrition, and drugs. Bacteriophages, via lytic cycles and lysogenic conversion, influence the gut microbiota composition and microbial community structure. Gaining an understanding of these processes is crucial to appreciating their contribution to the stability and variety of microbes. Recent research highlights the gut phageome's potential for therapeutic interventions by demonstrating its substantial influence on immunological responses and metabolic problems. The study of phage-microbiota interactions has been transformed by cutting-edge technologies, including high-throughput sequencing, CRISPR-Cas systems, and viral metagenomics, which allow for thorough research and the creation of new therapeutics. Even though tailored medicine and pathogen management hold great potential, obstacles such as regulatory difficulties and bacterial resistance call for additional investigation. Phage-based therapeutic strategies are rapidly advancing, ranging from genetically engineered phages and phages with modified capsid proteins designed to enhance efficacy to phage cocktails that target multiple bacterial strains.
The diversified ecology of microorganisms, including bacteria, archaea, fungi, protozoa, and viruses known collectively as the gut microbiota, which includes bacteriophages, is crucial to human health because it affects functions like immune system regulation, vitamin production, and pathogen protection. Bacteriophages are viruses that infect bacteria and are increasingly recognized as a viable treatment option for antibiotic-resistant strains, owing to their high host specificity, which enables precise targeting of drug-resistant bacteria while sparing commensal microbiota. The complex relationships between bacteriophages and gut microbiota are examined, with emphasis on their roles in maintaining health and contributing to disease. Gut microbiota homeostasis is influenced by a number of factors, including age, nutrition, and drugs. Bacteriophages, via lytic cycles and lysogenic conversion, influence the gut microbiota composition and microbial community structure. Gaining an understanding of these processes is crucial to appreciating their contribution to the stability and variety of microbes. Recent research highlights the gut phageome's potential for therapeutic interventions by demonstrating its substantial influence on immunological responses and metabolic problems. The study of phage-microbiota interactions has been transformed by cutting-edge technologies, including high-throughput sequencing, CRISPR-Cas systems, and viral metagenomics, which allow for thorough research and the creation of new therapeutics. Even though tailored medicine and pathogen management hold great potential, obstacles such as regulatory difficulties and bacterial resistance call for additional investigation. Phage-based therapeutic strategies are rapidly advancing, ranging from genetically engineered phages and phages with modified capsid proteins designed to enhance efficacy to phage cocktails that target multiple bacterial strains.The diversified ecology of microorganisms, including bacteria, archaea, fungi, protozoa, and viruses known collectively as the gut microbiota, which includes bacteriophages, is crucial to human health because it affects functions like immune system regulation, vitamin production, and pathogen protection. Bacteriophages are viruses that infect bacteria and are increasingly recognized as a viable treatment option for antibiotic-resistant strains, owing to their high host specificity, which enables precise targeting of drug-resistant bacteria while sparing commensal microbiota. The complex relationships between bacteriophages and gut microbiota are examined, with emphasis on their roles in maintaining health and contributing to disease. Gut microbiota homeostasis is influenced by a number of factors, including age, nutrition, and drugs. Bacteriophages, via lytic cycles and lysogenic conversion, influence the gut microbiota composition and microbial community structure. Gaining an understanding of these processes is crucial to appreciating their contribution to the stability and variety of microbes. Recent research highlights the gut phageome's potential for therapeutic interventions by demonstrating its substantial influence on immunological responses and metabolic problems. The study of phage-microbiota interactions has been transformed by cutting-edge technologies, including high-throughput sequencing, CRISPR-Cas systems, and viral metagenomics, which allow for thorough research and the creation of new therapeutics. Even though tailored medicine and pathogen management hold great potential, obstacles such as regulatory difficulties and bacterial resistance call for additional investigation. Phage-based therapeutic strategies are rapidly advancing, ranging from genetically engineered phages and phages with modified capsid proteins designed to enhance efficacy to phage cocktails that target multiple bacterial strains.
Author Alibabaei, Farnaz
Eslami, Majid
Paraandavaji, Elham
Dehghan, Parmida
Naderian, Ramtin
Author_xml – sequence: 1
  givenname: Ramtin
  surname: Naderian
  fullname: Naderian, Ramtin
– sequence: 2
  givenname: Farnaz
  surname: Alibabaei
  fullname: Alibabaei, Farnaz
– sequence: 3
  givenname: Elham
  surname: Paraandavaji
  fullname: Paraandavaji, Elham
– sequence: 4
  givenname: Parmida
  surname: Dehghan
  fullname: Dehghan, Parmida
– sequence: 5
  givenname: Majid
  orcidid: 0000-0001-5118-678X
  surname: Eslami
  fullname: Eslami, Majid
BackLink https://www.ncbi.nlm.nih.gov/pubmed/41032194$$D View this record in MEDLINE/PubMed
BookMark eNo9kD1PwzAURS1URD_gDzAgjywBP9txGjaEoK1UBBJlQ7Kc5Lk1SpMSOwP99QRSOt0n3fPucMZkUNUVEnIJ7AYYS249cMV4xHgcAUumMtqfkBFMVRKBADk43kwNydj7T8aUEpydkaEEJjikckQ-XjdmjdGzy5s6c3UwdFEFbEweXF156ioaNkhnbbiji-2udLnpC1s3dI6mDBtqqoKuNt3PDtvgcvoWGhNw7dCfk1NrSo8Xh5yQ96fH1cM8Wr7MFg_3yyjnsQpRLnmhLAcjUfBYCl6wOEFMrLSQ2TTDrDCZzZnCzMo0zYopT4yA2LJUFSCsmJDrfnfX1F8t-qC3zudYlqbCuvW6W1UAwKXs0KsD2mZbLPSucVvTfOt_Ix3Ae6AT4n2D9ogA07_ada9dd9r1n3a9Fz-IPnXc
Cites_doi 10.3390/microorganisms8091420
10.1016/j.chom.2019.01.008
10.3389/fmicb.2024.1379382
10.1136/gutjnl-2019-320005
10.1038/s41421-025-00789-x
10.3389/fphar.2022.901559
10.1093/femsre/fuv048
10.1016/j.jare.2022.09.012
10.1186/s12917-023-03724-y
10.1128/AAC.01774-15
10.1016/j.chom.2019.01.018
10.3389/fmed.2024.1432703
10.1038/s41385-019-0250-5
10.1016/j.chom.2019.01.017
10.1038/nbt.3011
10.3389/fmicb.2023.1078760
10.1007/s00253-014-5643-5
10.1080/19490976.2022.2107866
10.1016/j.cell.2015.01.002
10.1080/19490976.2024.2309684
10.1038/s41591-019-0437-z
10.3390/cells13231987
10.1093/bib/bbae117
10.3390/antibiotics8030131
10.3390/microorganisms11102454
10.23736/S2724-6507.22.03752-6
10.1007/s00262-017-2076-x
10.1016/j.tim.2023.04.008
10.3389/fimmu.2024.1398652
10.1016/j.chom.2020.08.003
10.3390/pharmaceutics15102416
10.1080/19490976.2022.2113717
10.1007/s12602-025-10513-6
10.1053/j.gastro.2020.09.056
10.1371/journal.pone.0105221
10.1126/sciimmunol.abn6660
10.1038/s41598-025-12299-7
10.3389/fphar.2023.1166022
10.1016/j.ebiom.2022.104113
10.1038/nrmicro.2017.30
10.1038/s41590-019-0513-z
10.1038/s41396-021-01107-5
10.1007/s00284-022-03112-z
10.3389/fimmu.2022.1050895
10.1016/j.ebiom.2015.12.023
10.1016/j.chom.2020.08.005
10.1007/s00535-022-01882-8
10.1038/s41564-021-00928-6
10.1016/j.crmeth.2022.100383
10.7150/ijbs.60551
10.3390/v17030390
10.3389/fendo.2019.00784
10.1038/s41564-024-01832-5
10.1053/j.gastro.2016.11.010
10.1038/nm.3950
10.1016/j.tim.2021.04.007
10.3390/cells9041013
10.1016/j.msard.2024.105530
10.1136/gutjnl-2018-318131
10.4049/jimmunol.2300480
10.3390/medsci6040086
10.1073/pnas.1305923110
10.3390/microorganisms13020295
10.4161/bact.1.2.14590
10.1016/j.copbio.2020.11.003
10.1016/j.tim.2018.10.008
10.1371/journal.pbio.3002083
10.1016/j.chempr.2024.06.004
10.3389/fmicb.2023.1320345
10.1016/j.nmni.2021.100887
10.3389/fphar.2022.897926
10.3390/v10070386
10.1016/bs.pmbts.2023.04.007
10.1016/j.vetmic.2023.109923
10.1038/npjbiofilms.2016.10
10.1093/synbio/ysy002
10.3390/biom15010093
10.1038/s41423-020-00532-4
10.1002/jcp.28333
10.1016/j.msard.2024.105973
10.1038/s41598-022-25979-5
10.1016/j.jgg.2024.01.002
10.1016/j.intimp.2022.109545
10.1002/imt2.70048
10.1007/s12551-023-01124-y
10.3390/microorganisms11051181
10.1016/j.chom.2019.05.001
10.1002/eji.202451543
10.3390/idr16060092
ContentType Journal Article
Copyright 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Copyright_xml – notice: 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1007/s12602-025-10784-z
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1867-1314
ExternalDocumentID 41032194
10_1007_s12602_025_10784_z
Genre Journal Article
Review
GroupedDBID ---
06C
06D
0R~
0VY
203
29O
2JY
2KG
2~H
30V
4.4
406
408
409
40E
53G
67N
6NX
875
96X
AACDK
AAHBH
AAHNG
AAIAL
AAJBT
AAJKR
AANZL
AAPKM
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYXX
AAZMS
ABAKF
ABBRH
ABBXA
ABDBE
ABDZT
ABECU
ABFSG
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABMQK
ABQBU
ABRTQ
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSTC
ACZOJ
ADHHG
ADHIR
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEFQL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFOHR
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHPBZ
AHWEU
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJRNO
AJZVZ
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
AOCGG
ASPBG
ATHPR
AUKKA
AVWKF
AXYYD
AYFIA
AYJHY
AZFZN
BA0
BENPR
BGNMA
BHPHI
CITATION
CSCUP
DDRTE
DNIVK
DPUIP
EBLON
EBS
EIOEI
ESBYG
F5P
FERAY
FFXSO
FIGPU
FNLPD
FRRFC
FYJPI
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GQ7
GQ8
GXS
HCIFZ
HG6
HLICF
HMJXF
HQYDN
HRMNR
I0C
IJ-
IKXTQ
IWAJR
IXC
IXD
IZIGR
I~X
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KOV
LLZTM
M4Y
NPVJJ
NQJWS
O93
O9I
O9J
OAM
PT4
QOR
QOS
R89
RLLFE
ROL
RSV
S1Z
S27
S3A
S3B
SBL
SDH
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
STPWE
T13
TSG
U2A
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
Z45
ZMTXR
~A9
AAYZH
AESKC
NPM
7X8
ID FETCH-LOGICAL-c256t-c42d6f21a4e325432d057ee7f4f1bf9bebdabfc06ebf499bd827a315f096d13f3
IEDL.DBID RSV
ISICitedReferencesCount 0
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001585021400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1867-1306
1867-1314
IngestDate Mon Oct 06 16:26:47 EDT 2025
Thu Oct 02 04:48:59 EDT 2025
Sat Nov 29 07:22:56 EST 2025
IsPeerReviewed true
IsScholarly true
Keywords Bacteriophages
Gut microbiota
Microbial diversity
Phage therapy
Immune modulation
Language English
License 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c256t-c42d6f21a4e325432d057ee7f4f1bf9bebdabfc06ebf499bd827a315f096d13f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0001-5118-678X
PMID 41032194
PQID 3256111244
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3256111244
pubmed_primary_41032194
crossref_primary_10_1007_s12602_025_10784_z
PublicationCentury 2000
PublicationDate 2025-10-01
PublicationDateYYYYMMDD 2025-10-01
PublicationDate_xml – month: 10
  year: 2025
  text: 2025-10-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Probiotics and antimicrobial proteins
PublicationTitleAlternate Probiotics Antimicrob Proteins
PublicationYear 2025
References BB Hsu (10784_CR35) 2019; 25
S Nayfach (10784_CR48) 2021; 6
M Palma (10784_CR90) 2024; 16
A Salek Farrokhi (10784_CR53) 2019; 234
R Monteiro (10784_CR80) 2019; 27
V Dinakaran (10784_CR22) 2014; 9
L Gogokhia (10784_CR29) 2019; 25
N Kobyliak (10784_CR30) 2022; 47
G Zampieri (10784_CR65) 2023; 3
M Khan Mirzaei (10784_CR64) 2022; 30
B Gutiérrez (10784_CR79) 2020; 8
S Kaur (10784_CR26) 2014; 98
L De Sordi (10784_CR41) 2019; 25
X Yu (10784_CR50) 2024
L Li (10784_CR19) 2025; 11
X Li (10784_CR91) 2021; 17
KE Schackart (10784_CR70) 2023
CB Silveira (10784_CR15) 2016; 2
Z Cao (10784_CR44) 2022
B Gaborieau (10784_CR67) 2024; 9
G Tong (10784_CR23) 2022; 13
M Gliźniewicz (10784_CR16) 2024; 14
W Nie (10784_CR66) 2024; 25
L Li (10784_CR84) 2024; 288
F Jamali (10784_CR24) 2025; 17
RJ Citorik (10784_CR73) 2014; 32
SJ Ott (10784_CR57) 2017; 152
M Hosokawa (10784_CR68) 2024; 16
H Tahmasebi (10784_CR9) 2025
TS Rasmussen (10784_CR59) 2020; 69
A Boix-Amorós (10784_CR62) 2022; 14
M Rustad (10784_CR75) 2018; 3
RM Dedrick (10784_CR88) 2019; 25
H Shuwen (10784_CR7) 2022; 14
Y Zhang (10784_CR14) 2023; 11
M Karbalaei (10784_CR92) 2021; 42
Y Li (10784_CR36) 2024
SC Emencheta (10784_CR1) 2023; 15
A Brunse (10784_CR58) 2022; 16
AC Gregory (10784_CR69) 2020; 28
S Roux (10784_CR71) 2023; 21
Y-K Qi (10784_CR74) 2024; 10
A Paule (10784_CR94) 2018
C Loc-Carrillo (10784_CR45) 2011; 1
A Naseri (10784_CR17) 2024; 92
P Murgas (10784_CR34) 2018; 67
C Wang (10784_CR3) 2025; 4
BR Lenneman (10784_CR76) 2021; 68
S Sanaie (10784_CR18) 2024; 85
S Federici (10784_CR11) 2021; 18
C Dai (10784_CR93) 2023; 114
MK Mirzaei (10784_CR39) 2017; 15
F Chen (10784_CR21) 2023; 49
F Chen (10784_CR8) 2023; 14
ES Lim (10784_CR49) 2015; 21
T Zuo (10784_CR52) 2019; 68
JY Nale (10784_CR82) 2016; 60
M Lee (10784_CR56) 2021; 160
HT Le (10784_CR28) 2025; 55
T Zuo (10784_CR46) 2020; 28
SC Emencheta (10784_CR47) 2023
RA Edwards (10784_CR72) 2016; 40
M Maronek (10784_CR83) 2020; 9
J Callanan (10784_CR6) 2018
SA Sarker (10784_CR38) 2016; 4
TD Sutton (10784_CR4) 2019; 10
S Divya Ganeshan (10784_CR95) 2019; 8
10784_CR78
Z Pei (10784_CR12) 2024; 16
J Qu (10784_CR86) 2024; 11
K Champagne-Jorgensen (10784_CR27) 2023; 31
L Chen (10784_CR43) 2023; 11
K Han (10784_CR77) 2024; 212
Y Zhang (10784_CR51) 2023
X Yu (10784_CR5) 2024; 15
AN Shkoporov (10784_CR42) 2019; 25
C Chen (10784_CR60) 2023
F Adiliaghdam (10784_CR33) 2022; 7
P Villoslada-Blanco (10784_CR61) 2022; 12
T Imai (10784_CR54) 2022; 57
JM Norman (10784_CR31) 2015; 160
L Zheng (10784_CR89) 2024; 51
JJ Barr (10784_CR25) 2013; 110
MA Hemmati (10784_CR63) 2024; 13
M Galtier (10784_CR81) 2017; 11
S Sedighi (10784_CR20) 2023; 80
M Eslami (10784_CR96) 2025; 13
Z Zhu (10784_CR2) 2022
S Nechat (10784_CR55) 2025; 15
L Liu (10784_CR32) 2019; 20
R Sausset (10784_CR10) 2020; 13
N Nguyen (10784_CR40) 2019; 28
X Mao (10784_CR85) 2023; 19
M Eslami (10784_CR13) 2025; 17
Z Naureen (10784_CR37) 2020; 91
SN Peerayeh (10784_CR87) 2016; 11
References_xml – volume: 8
  issue: 9
  year: 2020
  ident: 10784_CR79
  publication-title: Microorganisms
  doi: 10.3390/microorganisms8091420
– volume: 25
  start-page: 285
  issue: 2
  year: 2019
  ident: 10784_CR29
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2019.01.008
– year: 2024
  ident: 10784_CR50
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2024.1379382
– volume: 69
  start-page: 2122
  issue: 12
  year: 2020
  ident: 10784_CR59
  publication-title: Gut
  doi: 10.1136/gutjnl-2019-320005
– volume: 11
  start-page: 25
  issue: 1
  year: 2025
  ident: 10784_CR19
  publication-title: Cell Discov
  doi: 10.1038/s41421-025-00789-x
– volume: 13
  year: 2022
  ident: 10784_CR23
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2022.901559
– volume: 40
  start-page: 258
  issue: 2
  year: 2016
  ident: 10784_CR72
  publication-title: FEMS Microbiol Rev
  doi: 10.1093/femsre/fuv048
– volume: 49
  start-page: 103
  year: 2023
  ident: 10784_CR21
  publication-title: J Adv Res
  doi: 10.1016/j.jare.2022.09.012
– volume: 28
  start-page: 5
  issue: 5
  year: 2019
  ident: 10784_CR40
  publication-title: Cochrane Database Syst Rev
– volume: 19
  start-page: 165
  issue: 1
  year: 2023
  ident: 10784_CR85
  publication-title: BMC Vet Res
  doi: 10.1186/s12917-023-03724-y
– volume: 60
  start-page: 968
  issue: 2
  year: 2016
  ident: 10784_CR82
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.01774-15
– volume: 25
  start-page: 210
  issue: 2
  year: 2019
  ident: 10784_CR41
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2019.01.018
– volume: 11
  start-page: 1432703
  year: 2024
  ident: 10784_CR86
  publication-title: Phage therapy of extensively drug resistant Acinetobacter baumannii infections: evaluating the distribution of phage in human body and the impact on gut microbiome
  doi: 10.3389/fmed.2024.1432703
– volume: 13
  start-page: 205
  issue: 2
  year: 2020
  ident: 10784_CR10
  publication-title: Mucosal Immunol
  doi: 10.1038/s41385-019-0250-5
– volume: 25
  start-page: 195
  issue: 2
  year: 2019
  ident: 10784_CR42
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2019.01.017
– volume: 32
  start-page: 1141
  issue: 11
  year: 2014
  ident: 10784_CR73
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3011
– year: 2023
  ident: 10784_CR70
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2023.1078760
– volume: 98
  start-page: 4653
  year: 2014
  ident: 10784_CR26
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-014-5643-5
– volume: 11
  start-page: e60127
  issue: 2
  year: 2016
  ident: 10784_CR87
  publication-title: High frequency of extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates from male patients' urine
– volume: 14
  start-page: 2107866
  issue: 1
  year: 2022
  ident: 10784_CR62
  publication-title: Gut Microbes
  doi: 10.1080/19490976.2022.2107866
– volume: 160
  start-page: 447
  issue: 3
  year: 2015
  ident: 10784_CR31
  publication-title: Cell
  doi: 10.1016/j.cell.2015.01.002
– volume: 16
  issue: 1
  year: 2024
  ident: 10784_CR12
  publication-title: Gut Microbes
  doi: 10.1080/19490976.2024.2309684
– volume: 25
  start-page: 730
  issue: 5
  year: 2019
  ident: 10784_CR88
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0437-z
– volume: 13
  issue: 23
  year: 2024
  ident: 10784_CR63
  publication-title: Cells
  doi: 10.3390/cells13231987
– volume: 25
  issue: 3
  year: 2024
  ident: 10784_CR66
  publication-title: Brief Bioinform
  doi: 10.1093/bib/bbae117
– volume: 8
  start-page: 131
  issue: 3
  year: 2019
  ident: 10784_CR95
  publication-title: Antibiotics
  doi: 10.3390/antibiotics8030131
– year: 2023
  ident: 10784_CR51
  publication-title: Microorganisms
  doi: 10.3390/microorganisms11102454
– volume: 47
  start-page: 242
  issue: 2
  year: 2022
  ident: 10784_CR30
  publication-title: Minerva Endocrinol
  doi: 10.23736/S2724-6507.22.03752-6
– volume: 67
  start-page: 183
  issue: 2
  year: 2018
  ident: 10784_CR34
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-017-2076-x
– volume: 11
  start-page: 840
  issue: 7
  year: 2017
  ident: 10784_CR81
  publication-title: J Crohns Colitis
– volume: 31
  start-page: 1058
  issue: 10
  year: 2023
  ident: 10784_CR27
  publication-title: Trends Microbiol
  doi: 10.1016/j.tim.2023.04.008
– year: 2024
  ident: 10784_CR36
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2024.1398652
– volume: 28
  start-page: 724
  issue: 5
  year: 2020
  ident: 10784_CR69
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.08.003
– volume: 15
  start-page: 2416
  issue: 10
  year: 2023
  ident: 10784_CR1
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics15102416
– volume: 14
  issue: 1
  year: 2022
  ident: 10784_CR7
  publication-title: Gut Microbes
  doi: 10.1080/19490976.2022.2113717
– volume: 17
  start-page: 2112
  issue: 4
  year: 2025
  ident: 10784_CR24
  publication-title: Probiotics Antimicrob Proteins
  doi: 10.1007/s12602-025-10513-6
– volume: 160
  start-page: 524
  issue: 2
  year: 2021
  ident: 10784_CR56
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.09.056
– volume: 9
  issue: 8
  year: 2014
  ident: 10784_CR22
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0105221
– volume: 7
  issue: 70
  year: 2022
  ident: 10784_CR33
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abn6660
– volume: 11
  start-page: 2454
  issue: 10
  year: 2023
  ident: 10784_CR14
  publication-title: Microorganisms
  doi: 10.3390/microorganisms11102454
– volume: 15
  start-page: 26875
  issue: 1
  year: 2025
  ident: 10784_CR55
  publication-title: Sci Rep
  doi: 10.1038/s41598-025-12299-7
– volume: 14
  year: 2023
  ident: 10784_CR8
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2023.1166022
– year: 2022
  ident: 10784_CR44
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2022.104113
– volume: 15
  start-page: 397
  issue: 7
  year: 2017
  ident: 10784_CR39
  publication-title: Nat Rev Microbiol
  doi: 10.1038/nrmicro.2017.30
– volume: 20
  start-page: 1681
  issue: 12
  year: 2019
  ident: 10784_CR32
  publication-title: Nat Immunol
  doi: 10.1038/s41590-019-0513-z
– volume: 16
  start-page: 686
  issue: 3
  year: 2022
  ident: 10784_CR58
  publication-title: ISME J
  doi: 10.1038/s41396-021-01107-5
– volume: 80
  start-page: 15
  issue: 1
  year: 2023
  ident: 10784_CR20
  publication-title: Curr Microbiol
  doi: 10.1007/s00284-022-03112-z
– year: 2023
  ident: 10784_CR60
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.1050895
– volume: 4
  start-page: 124
  year: 2016
  ident: 10784_CR38
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2015.12.023
– volume: 28
  start-page: 741
  issue: 5
  year: 2020
  ident: 10784_CR46
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.08.005
– year: 2023
  ident: 10784_CR47
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics15102416
– volume: 57
  start-page: 559
  issue: 8
  year: 2022
  ident: 10784_CR54
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-022-01882-8
– volume: 6
  start-page: 960
  issue: 7
  year: 2021
  ident: 10784_CR48
  publication-title: Nat Microbiol
  doi: 10.1038/s41564-021-00928-6
– volume: 3
  issue: 1
  year: 2023
  ident: 10784_CR65
  publication-title: Cell Rep Methods
  doi: 10.1016/j.crmeth.2022.100383
– volume: 17
  start-page: 3573
  issue: 13
  year: 2021
  ident: 10784_CR91
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.60551
– volume: 17
  start-page: 390
  issue: 3
  year: 2025
  ident: 10784_CR13
  publication-title: Viruses
  doi: 10.3390/v17030390
– volume: 10
  year: 2019
  ident: 10784_CR4
  publication-title: Front Endocrinol
  doi: 10.3389/fendo.2019.00784
– volume: 9
  start-page: 2847
  issue: 11
  year: 2024
  ident: 10784_CR67
  publication-title: Nat Microbiol
  doi: 10.1038/s41564-024-01832-5
– volume: 152
  start-page: 799
  issue: 4
  year: 2017
  ident: 10784_CR57
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.11.010
– volume: 21
  start-page: 1228
  issue: 10
  year: 2015
  ident: 10784_CR49
  publication-title: Nat Med
  doi: 10.1038/nm.3950
– volume: 30
  start-page: 131
  issue: 2
  year: 2022
  ident: 10784_CR64
  publication-title: Trends Microbiol
  doi: 10.1016/j.tim.2021.04.007
– volume: 9
  start-page: 1013
  issue: 4
  year: 2020
  ident: 10784_CR83
  publication-title: Cells
  doi: 10.3390/cells9041013
– volume: 85
  year: 2024
  ident: 10784_CR18
  publication-title: Mult Scler Relat Disord
  doi: 10.1016/j.msard.2024.105530
– volume: 68
  start-page: 1169
  issue: 7
  year: 2019
  ident: 10784_CR52
  publication-title: Gut
  doi: 10.1136/gutjnl-2018-318131
– volume: 15
  year: 2024
  ident: 10784_CR5
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2024.1379382
– volume: 212
  start-page: 208
  issue: 2
  year: 2024
  ident: 10784_CR77
  publication-title: J Immunol
  doi: 10.4049/jimmunol.2300480
– year: 2018
  ident: 10784_CR94
  publication-title: Med Sci
  doi: 10.3390/medsci6040086
– volume: 110
  start-page: 10771
  issue: 26
  year: 2013
  ident: 10784_CR25
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1305923110
– volume: 13
  start-page: 295
  issue: 2
  year: 2025
  ident: 10784_CR96
  publication-title: Microorganisms
  doi: 10.3390/microorganisms13020295
– volume: 91
  issue: 13-s
  year: 2020
  ident: 10784_CR37
  publication-title: Acta Biomed
– volume: 1
  start-page: 111
  issue: 2
  year: 2011
  ident: 10784_CR45
  publication-title: Bacteriophage
  doi: 10.4161/bact.1.2.14590
– volume: 68
  start-page: 151
  year: 2021
  ident: 10784_CR76
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2020.11.003
– volume: 27
  start-page: 368
  issue: 4
  year: 2019
  ident: 10784_CR80
  publication-title: Trends Microbiol
  doi: 10.1016/j.tim.2018.10.008
– volume: 21
  issue: 4
  year: 2023
  ident: 10784_CR71
  publication-title: PLoS Biol
  doi: 10.1371/journal.pbio.3002083
– volume: 10
  start-page: 2390
  issue: 8
  year: 2024
  ident: 10784_CR74
  publication-title: Chem
  doi: 10.1016/j.chempr.2024.06.004
– volume: 14
  start-page: 1320345
  year: 2024
  ident: 10784_CR16
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2023.1320345
– volume: 42
  year: 2021
  ident: 10784_CR92
  publication-title: New Microbes New Infect
  doi: 10.1016/j.nmni.2021.100887
– year: 2022
  ident: 10784_CR2
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2022.897926
– year: 2018
  ident: 10784_CR6
  publication-title: Viruses
  doi: 10.3390/v10070386
– ident: 10784_CR78
  doi: 10.1016/bs.pmbts.2023.04.007
– volume: 288
  year: 2024
  ident: 10784_CR84
  publication-title: Vet Microbiol
  doi: 10.1016/j.vetmic.2023.109923
– volume: 2
  start-page: 16010
  year: 2016
  ident: 10784_CR15
  publication-title: NPJ Biofilms Microbiomes
  doi: 10.1038/npjbiofilms.2016.10
– volume: 3
  issue: 1
  year: 2018
  ident: 10784_CR75
  publication-title: Synth Biol
  doi: 10.1093/synbio/ysy002
– year: 2025
  ident: 10784_CR9
  publication-title: Biomolecules
  doi: 10.3390/biom15010093
– volume: 18
  start-page: 889
  issue: 4
  year: 2021
  ident: 10784_CR11
  publication-title: Cell Mol Immunol
  doi: 10.1038/s41423-020-00532-4
– volume: 234
  start-page: 14941
  issue: 9
  year: 2019
  ident: 10784_CR53
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.28333
– volume: 92
  start-page: 105973
  year: 2024
  ident: 10784_CR17
  publication-title: Mult Scler Relat Disord
  doi: 10.1016/j.msard.2024.105973
– volume: 12
  start-page: 21658
  issue: 1
  year: 2022
  ident: 10784_CR61
  publication-title: Sci Rep
  doi: 10.1038/s41598-022-25979-5
– volume: 51
  start-page: 479
  issue: 5
  year: 2024
  ident: 10784_CR89
  publication-title: J Genet Genomics
  doi: 10.1016/j.jgg.2024.01.002
– volume: 114
  year: 2023
  ident: 10784_CR93
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2022.109545
– volume: 4
  issue: 4
  year: 2025
  ident: 10784_CR3
  publication-title: Imeta
  doi: 10.1002/imt2.70048
– volume: 16
  start-page: 69
  issue: 1
  year: 2024
  ident: 10784_CR68
  publication-title: Biophys Rev
  doi: 10.1007/s12551-023-01124-y
– volume: 11
  start-page: 1181
  issue: 5
  year: 2023
  ident: 10784_CR43
  publication-title: Microorganisms
  doi: 10.3390/microorganisms11051181
– volume: 25
  start-page: 803
  issue: 6
  year: 2019
  ident: 10784_CR35
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2019.05.001
– volume: 55
  issue: 3
  year: 2025
  ident: 10784_CR28
  publication-title: Eur J Immunol
  doi: 10.1002/eji.202451543
– volume: 16
  start-page: 1127
  issue: 6
  year: 2024
  ident: 10784_CR90
  publication-title: Infect Dis Rep
  doi: 10.3390/idr16060092
SSID ssj0066320
Score 2.3403878
SecondaryResourceType review_article
online_first
Snippet The diversified ecology of microorganisms, including bacteria, archaea, fungi, protozoa, and viruses known collectively as the gut microbiota, which includes...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Title Phage-Microbiota Interactions in the Gut: Implications for Health and Therapeutic Strategies
URI https://www.ncbi.nlm.nih.gov/pubmed/41032194
https://www.proquest.com/docview/3256111244
WOSCitedRecordID wos001585021400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: Springer Nature Link Journals
  customDbUrl:
  eissn: 1867-1314
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0066320
  issn: 1867-1306
  databaseCode: RSV
  dateStart: 20090601
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEB5q8eDF96M-ygrSi13MJpvNxpuIL9BStJYehJBNdqWXVJpUaH-9k6S1Feyhx0DYXWaWmW8y-b4BuEA_M88yLtXSdynmY4v6EXeoiizf6IhHbtFo7z57rZbs9fx2BZpLO_hXKUPIbdN87CqWKpLTCQZcJux8XMHrW3cWdjFzFhqMuUAbxcAspgyZ_5f4m4WWQMsixdxvrXa4bdicQklyU_p-Byo62YVGu9SiHjdJZ06tSpukQdpzlerxHnzg46emL_1SiSkLSfFxsOQ5pKSfEISG5GGUXZOnhb_OCYJcUnKXSJjEi5uQmdKtTvfh_f6uc_tIp6MWaISYJ6MRt2NhbBZy7eT0eDtGHKe1Z7hhyvhKqzhUJrKEVgZrJBVL2wsd5hqsgGLmGOcAqskg0UdAZP4q4g5XGIcLYfvKSD92paeYJx2la3A5M33wVSpqBHPt5NycAZozKMwZTGpwPvNOgBc_72aEiR6M0gDPKTBQIzypwWHptt_1eC4TyHx-vNJeJ7Bhl56kFjuFajYc6TNYj76zfjqsw5rXk_Xizv0A6V_Nyg
linkProvider Springer Nature
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phage-Microbiota+Interactions+in+the+Gut%3A+Implications+for+Health+and+Therapeutic+Strategies&rft.jtitle=Probiotics+and+antimicrobial+proteins&rft.au=Naderian%2C+Ramtin&rft.au=Alibabaei%2C+Farnaz&rft.au=Paraandavaji%2C+Elham&rft.au=Dehghan%2C+Parmida&rft.date=2025-10-01&rft.issn=1867-1314&rft.eissn=1867-1314&rft_id=info:doi/10.1007%2Fs12602-025-10784-z&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1867-1306&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1867-1306&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1867-1306&client=summon